Effient

Effient is a brand name of prasugrel, approved by the FDA in the following formulation(s):

EFFIENT (prasugrel hydrochloride - tablet; oral)

• 
  Manufacturer: ELI LILLY AND CO
  
  Approval date: July 10, 2009
  
  Strength(s): EQ 10MG BASE ^[RLD], EQ 5MG BASE
  

Has a generic version of Effient been approved?

No. There is currently no therapeutically equivalent version of Effient available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Effient. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
  Patent 5,288,726
  Issued: February 22, 1994
  Inventor(s): Koike; Hiroyuki & Asai; Fumitoshi & Sugidachi; Atsuhiro & Kimura; Tomio & Inoue; Teruhiko & Nishino; Shigeyoshi & Tsuzaki; Yasunori
  Assignee(s): Ube Industries Limited
  Sankyo Company, Limited
  Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkanesulfonyl or sulfamoyl; R.sup.2 is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.
  
  Patent expiration dates:
  
  
  • April 14, 2017
    
    ✓ 
    Patent use: TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Acid addition salts of hydropyridine derivatives
  Patent 6,693,115
  Issued: February 17, 2004
  Inventor(s): Fumitoshi; Asai & Taketoshi; Ogawa & Hideo; Naganuma & Naotoshi; Yamamura & Teruhiko; Inoue & Kazuyoshi; Nakamura
  Assignee(s): Sankyo Company, Limited
  Ube Industries Ltd.
  Acid addition salts of 2-acetoxy-5-(&agr;-cyclopropyl-carbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]-pyridine. The acid addition salts of tetrahydrothienopyridine derivatives of the present invention exhibit excellent oral absorption, metabolization into the active compound, and platelet aggregation-inhibiting effects, low toxicity, and excellent storage and handling stabilities, and are useful as medicaments, preferably preventive or therapeutic agents (particularly therapeutic agents) for diseases caused by a thrombus or an embolus, still more preferably preventive or therapeutic agents (particularly therapeutic agents) for thrombosis or embolism.
  
  Patent expiration dates:
  
  
  • July 3, 2021
    
    ✓ 
    Patent use: TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 10, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Effient Consumer Information (Drugs.com)
• Effient Consumer Information (Wolters Kluwer)
• Effient Consumer Information (Cerner Multum)
• Effient Advanced Consumer Information (Micromedex)
• Effient AHFS DI Monographs (ASHP)
• Prasugrel Consumer Information (Wolters Kluwer)
• Prasugrel Consumer Information (Cerner Multum)
• Prasugrel Advanced Consumer Information (Micromedex)
• Prasugrel AHFS DI Monographs (ASHP)